Axsome Therapeutics Stock News

Axsome Therapeutics said that it was informed by the FDA that it should be able to perform a required inspection of a contract manufacturing facility prior to the PDUFA date in April.

Benzingas weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. This week, in tribute to Black History Month, the duel is between a pair of Black-owned companies in the biopharmaceutical sector : Axsome Therapeutics Inc. (NASDAQ: AXSM ) and Global Blood Therapeutics Inc. (NASDAQ: GBT ). The Case For Axsome Therapeutics: This New York City-based company was founded in 2012 by the Haitian-born Dr. Herriot Tabuteau , who has served as its chairman and CEO since the company began. Tabuteau has a Bachelor of Arts in molecular biology and biochemistry from Wesleyan University and an M.D. from Yale University School of Medicine. He previously worked as an analyst for Goldman Sachs (NYSE: GS ), where he specialized in healthcare analysis, and for HealthCor , a fund focused on healthcare and life sciences. Dr. Herriot Tabuteau Axsome Therapeutics, which has been publicly-traded since 2015, focuses on treating disorders impacting the central nervous system including depression, chronic pain, narcolepsy, fibromyalgia and Alzheimer''s disease.

Benzinga's weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. This week, in tribute to Black History Month, the du

The stock receives a positive analyst thumbs-up after it issues a business update.

The stock receives a positive analyst thumbs-up after it issues a business update.

These two biotechs have potential catalysts to look forward to in 2022.

Axsome (AXSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co

These three stocks are poised for a major breakout in 2022.

Gainers: Marin Software MRIN +43%, QuinStreet (QNST) +5%, Axsome Therapeutics (AXSM) +4%, CarParts.com PRTS +3%, Curis CRIS +3%.Losers: Annexon (ANNX) -5%, Dogness (DOGZ) -4%,

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

Amid the 2021 Biotech Bear market, most bio-stocks are trading at a deep bargain to their intrinsic value.Adding insult to injury, Axsome Therapeutics is hit by a delay in FDA decision due to COVID.

These stocks could rebound nicely in the new year.

During the last session, Axsome Therapeutics Inc. (NASDAQ:AXSM)s traded shares were 0.74 million, with the beta value of the company hitting 2.21. At the end of the trading day, the stocks price was $35.30, reflecting an intraday gain of 5.34% or $1.79. The 52-week high for the AXSM share is $87.24, that puts it down Axsome Therapeutics Inc. (NASDAQ: AXSM) Is Decrease -54.10%, So Heres What We Can Expect On The Upswing Read More »

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have earned an average rating of Buy from the thirteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1 year target price []

Related Stocks: PAYA , STL , CW , SI , CHK , PYCR , ACHC , SAVE , NOV , SBNY , FL , BLI , AXSM ,